Bladder tissue permeability and transport modelling of intravesical alum, lidocaine hydrochloride, methylprednisolone hemisuccinate and mitomycin C.
The aims of this study were to assess the tissue permeability of the bladder and to characterize the transport of four drugs displaying different physico-chemical properties and commonly used in intravesical delivery, through porcine bladder. The transport of aluminium through porcine bladder was assessed by using a vertical static diffusion cell. Lidocaine hydrochloride, methylprednisolone hemisuccinate and mitomycin C were tested by using three different experimental setups, including vertical static diffusion cell, microdialyseur and lab-patented device. Penetration results on different experimental setups were homogenous suggesting dependency on physico-chemical characteristics of drug and subsequent interaction with bladder wall structure. Oppositely, permeation varied consistently with experimental setup characteristics (i.e., permeation surface, receptor fluid volume and hydrodynamic). Mathematical modelling of drug transport through bladder wall is proposed considering scarce literature on this route of administration. Practical outcome of this study could drive compounding optimization towards improvement of safety and efficacy in patient undergoing intravesical administration.
Service Pharmaceutique, Plateforme FRIPHARM, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, F-69437 Lyon cedex 03, France; Laboratoire de Pharmacie Galénique Industrielle, Faculté de Pharmacie de Lyon, Plateforme FRIPHARM, EA 4169 "Fonctions Normales et Pathologiques de la Barrière Cutanée", Université Claude Bernard Lyon 1, 8 avenue Rockefeller, F-69373 Lyon cedex 08, France.
Céline
C
Moch
Service Pharmaceutique, Plateforme FRIPHARM, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, F-69437 Lyon cedex 03, France; Laboratoire de Pharmacie Galénique Industrielle, Faculté de Pharmacie de Lyon, Plateforme FRIPHARM, EA 4169 "Fonctions Normales et Pathologiques de la Barrière Cutanée", Université Claude Bernard Lyon 1, 8 avenue Rockefeller, F-69373 Lyon cedex 08, France.
Damien
D
Salmon
Service Pharmaceutique, Plateforme FRIPHARM, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, F-69437 Lyon cedex 03, France; Laboratoire de Pharmacie Galénique Industrielle, Faculté de Pharmacie de Lyon, Plateforme FRIPHARM, EA 4169 "Fonctions Normales et Pathologiques de la Barrière Cutanée", Université Claude Bernard Lyon 1, 8 avenue Rockefeller, F-69373 Lyon cedex 08, France.
Laura
L
Rodríguez Armesto
Service d'Urologie, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, F-69437 Lyon cedex 03, France.
Marc
M
Colombel
Service Pharmaceutique, Plateforme FRIPHARM, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, F-69437 Lyon cedex 03, France.
Christine
C
Pivot
Service Pharmaceutique, Plateforme FRIPHARM, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, F-69437 Lyon cedex 03, France; Laboratoire de Pharmacie Galénique Industrielle, Faculté de Pharmacie de Lyon, Plateforme FRIPHARM, EA 4169 "Fonctions Normales et Pathologiques de la Barrière Cutanée", Université Claude Bernard Lyon 1, 8 avenue Rockefeller, F-69373 Lyon cedex 08, France. Electronic address: fabrice.pirot@univ-lyon1.fr.
Fabrice
F
Pirot
D000283:Administration, Intravesical; D000534:Alum Compounds / Q000008:administration & dosage / Q000378:metabolism*; D000818:Animals; D001692:Biological Transport / Q000187:drug effects / Q000502:physiology; D008012:Lidocaine / Q000008:administration & dosage / Q000378:metabolism*; D016685:Mitomycin / Q000008:administration & dosage / Q000378:metabolism*; D009924:Organ Culture Techniques; D010539:Permeability / Q000187:drug effects; D013552:Swine; D001743:Urinary Bladder / Q000187:drug effects / Q000378:metabolism*
D000534:Alum Compounds; C041524:aluminum sulfate; D016685:Mitomycin; D008012:Lidocaine
Bladder; Fickian model; Intravesical drug delivery; Permeability